DE69429742D1 - 2-[1-(1,3-Thiazolin-2-yl)azetidin-3-yl]thio-carbapenem-Derivate - Google Patents

2-[1-(1,3-Thiazolin-2-yl)azetidin-3-yl]thio-carbapenem-Derivate

Info

Publication number
DE69429742D1
DE69429742D1 DE69429742T DE69429742T DE69429742D1 DE 69429742 D1 DE69429742 D1 DE 69429742D1 DE 69429742 T DE69429742 T DE 69429742T DE 69429742 T DE69429742 T DE 69429742T DE 69429742 D1 DE69429742 D1 DE 69429742D1
Authority
DE
Germany
Prior art keywords
thiazolin
group
azetidin
thio
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69429742T
Other languages
English (en)
Other versions
DE69429742T2 (de
Inventor
Takao Abe
Takeshi Isoda
Chisato Sato
Ado Mihira
Satoshi Tamai
Toshio Kumagai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Japan Inc
Original Assignee
Wyeth Lederle Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Lederle Japan Ltd filed Critical Wyeth Lederle Japan Ltd
Application granted granted Critical
Publication of DE69429742D1 publication Critical patent/DE69429742D1/de
Publication of DE69429742T2 publication Critical patent/DE69429742T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D477/00Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DE69429742T 1993-07-01 1994-06-30 2-[1-(1,3-Thiazolin-2-yl)azetidin-3-yl]thio-carbapenem-Derivate Expired - Lifetime DE69429742T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21330693 1993-07-01
JP7932094 1994-03-28
JP12204694 1994-05-12

Publications (2)

Publication Number Publication Date
DE69429742D1 true DE69429742D1 (de) 2002-03-14
DE69429742T2 DE69429742T2 (de) 2002-06-06

Family

ID=27302982

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69429742T Expired - Lifetime DE69429742T2 (de) 1993-07-01 1994-06-30 2-[1-(1,3-Thiazolin-2-yl)azetidin-3-yl]thio-carbapenem-Derivate
DE69433955T Expired - Lifetime DE69433955T2 (de) 1993-07-01 1994-06-30 2-(1-(1,3-Thiazolin-2-yl)azetidin-3-yl) thio-carbapenem-Derivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69433955T Expired - Lifetime DE69433955T2 (de) 1993-07-01 1994-06-30 2-(1-(1,3-Thiazolin-2-yl)azetidin-3-yl) thio-carbapenem-Derivate

Country Status (16)

Country Link
US (2) US5534510A (de)
EP (2) EP0632039B1 (de)
JP (1) JP2666118B2 (de)
KR (1) KR100331293B1 (de)
AT (2) ATE212636T1 (de)
AU (1) AU682510B2 (de)
CA (1) CA2127193C (de)
DE (2) DE69429742T2 (de)
DK (2) DK0924210T3 (de)
ES (2) ES2170080T3 (de)
FI (1) FI106962B (de)
HU (1) HU220609B1 (de)
IL (1) IL110161A (de)
NO (2) NO306780B1 (de)
PT (2) PT632039E (de)
TW (1) TW254943B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783703A (en) * 1993-07-01 1998-07-21 Lederle (Japan), Ltd. Sulfur-containing compounds method for their use and prodction
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
ATE201410T1 (de) * 1994-12-12 2001-06-15 Wyeth Lederle Japan Ltd Verfahren zur herstellung von 1-(4,5-dihydro)2- thiazolyl-3-azetidinthiolderivaten
TW420681B (en) * 1995-12-08 2001-02-01 Lederle Japan Ltd Carbapenem-3-carboxylic acid ester derivatives
PT913151E (pt) 1996-05-09 2002-11-29 Sankyo Co Composicoes de luta contra a helicobacter pylori que contem derivados de 1-metilcarbapenem como substancia activa
WO2000015640A1 (fr) * 1998-09-10 2000-03-23 Wyeth Lederle Japan, Ltd. Composes de carbapenem
KR100325375B1 (ko) * 2000-01-31 2002-03-06 박호군 이미다졸린 고리가 치환된 카바페넴 유도체
HUP0303204A3 (en) * 2000-11-16 2010-04-28 Sankyo Co 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
KR100441406B1 (ko) * 2001-09-05 2004-07-23 한국과학기술연구원 티아졸리딘 고리 치환체를 갖는 1-β-메틸 카바페넴유도체 및 그 제조 방법
KR100451670B1 (ko) * 2001-09-14 2004-10-08 한국화학연구원 내성균에 대해 항생작용을 갖는 카바페넴 유도체 및 이의제조방법
WO2003040146A1 (fr) 2001-11-05 2003-05-15 Sumitomo Pharmaceuticals Co., Ltd. Nouveaux composes carbapenem
TW200403244A (en) * 2002-05-14 2004-03-01 Sankyo Co 1β-Methylcarbapenem derivatives for oral use
AU2003301426A1 (en) 2002-10-18 2004-05-04 Meiji Seika Kaisha, Ltd. Malonic acid monoesters and process for producing the same
AU2003301425A1 (en) * 2002-10-18 2004-05-04 Meiji Seika Kaisha, Ltd. Process for producing carbapenem derivative and intermediate for use in the production
AU2003284546A1 (en) * 2002-11-13 2004-06-03 Kaneka Corporation Process for producing carbapenem compound for oral administration
CA2519794A1 (en) * 2003-04-08 2004-10-21 Sumitomo Pharmaceuticals Co., Ltd. Novel carbapenem compounds
JP2007516810A (ja) * 2003-12-30 2007-06-28 ライポソニックス, インコーポレイテッド 動作制御を有する超音波治療ヘッド
EP1627891A1 (de) * 2004-08-11 2006-02-22 Covion Organic Semiconductors GmbH Polymere zur Verwendung in elektrolumineszierenden Anordnungen
KR100599876B1 (ko) * 2004-08-31 2006-07-13 한국화학연구원 2-아릴메틸아제티딘 카바페넴 유도체 및 그의 제조방법
JPWO2006025475A1 (ja) * 2004-09-03 2008-05-08 大日本住友製薬株式会社 新規なカルバペネム化合物
JP2006176418A (ja) * 2004-12-21 2006-07-06 Kaneka Corp 経口投与用カルバペネム化合物の製造方法と新規β−ラクタム化合物
WO2006103999A1 (ja) * 2005-03-25 2006-10-05 Dainippon Sumitomo Pharma Co., Ltd. 新規なカルバペネム化合物
KR100723889B1 (ko) 2006-06-30 2007-05-31 주식회사 하이닉스반도체 직렬 입/출력 인터페이스를 가진 멀티 포트 메모리 소자
JP5013795B2 (ja) * 2006-09-25 2012-08-29 Meiji Seikaファルマ株式会社 経口投与用カルバペネム
EP2188287A4 (de) * 2007-09-20 2011-03-02 Kukje Pharm Ind Co Ltd Säurezusatzsalze aus synthetischen zwischenprodukten für carbapenem-antibiotika und verfahren zu ihrer herstellung
CN101868460A (zh) * 2007-11-23 2010-10-20 国际药品工业株式会社 2-芳基甲基吖丁啶-碳青霉烯-3-羧酸酯衍生物或其盐、其制备方法以及包含上述的药物组合物
CN102558181B (zh) * 2010-12-15 2015-04-22 石药集团中奇制药技术(石家庄)有限公司 一种碳青霉烯抗生素的制备方法
CN102731507B (zh) * 2011-04-13 2015-04-01 石药集团中奇制药技术(石家庄)有限公司 泰比培南晶型、其制备方法及其在制备药物中的应用
CN103059026A (zh) * 2011-10-20 2013-04-24 北京康健源科技有限公司 一种替比培南匹夫酯的制备方法
CN102584812B (zh) * 2011-11-18 2014-03-12 深圳万乐药业有限公司 一种泰比培南酯杂质的制备方法
CN102503940B (zh) * 2011-11-22 2013-12-25 深圳万乐药业有限公司 制备泰比培南酯开环杂质的方法
CN103059027A (zh) * 2012-12-20 2013-04-24 安徽悦康凯悦制药有限公司 替比培南匹伏酯的制备方法
JP7083828B2 (ja) * 2016-12-15 2022-06-13 スペロ セラピューティックス,インコーポレイテッド 新規テビペネムピボキシルの即放性および調節放出性経口剤形
NZ753781A (en) * 2017-02-06 2022-10-28 Spero Therapeutics Inc Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
CN110698469A (zh) * 2019-10-28 2020-01-17 南京红杉生物科技有限公司 泰比培南酯中间体及其合成方法、应用
WO2022104087A1 (en) 2020-11-11 2022-05-19 Spero Therapeutics, Inc. High dosage tebipenem pivoxil tablet formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3665001A (en) * 1970-06-11 1972-05-23 Exxon Research Engineering Co Azinyl organophosphorus compounds
JPS60202886A (ja) * 1984-03-27 1985-10-14 Sankyo Co Ltd 1―置換カルバペネム―3―カルボン酸誘導体
US4696923A (en) * 1984-04-23 1987-09-29 Merck & Co., Inc. 6-[1-hydroxyethyl]-2-SR8 -1-methyl-1-carbadethiapen-2-em-3-carboxylic acids
JPS63255280A (ja) * 1987-04-11 1988-10-21 Nippon Redarii Kk (1r,5s,6s)−2−置換−6−〔(r)−1−ヒドロキシエチル〕−1−メチル−カルバペネム−3−カルボン酸誘導体
GB9210096D0 (en) * 1992-05-11 1992-06-24 Fujisawa Pharmaceutical Co 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives and their preparation

Also Published As

Publication number Publication date
DE69429742T2 (de) 2002-06-06
ATE212636T1 (de) 2002-02-15
DK0924210T3 (da) 2004-12-13
PT924210E (pt) 2004-12-31
HU9401957D0 (en) 1994-09-28
EP0632039A1 (de) 1995-01-04
IL110161A (en) 1998-09-24
KR950003292A (ko) 1995-02-16
PT632039E (pt) 2002-06-28
NO991019D0 (no) 1999-03-02
FI943164A (fi) 1995-01-02
NO942483D0 (no) 1994-06-30
US5534510A (en) 1996-07-09
EP0632039B1 (de) 2002-01-30
US5679790A (en) 1997-10-21
KR100331293B1 (ko) 2002-10-25
HUT68057A (en) 1995-05-29
ATE273975T1 (de) 2004-09-15
NO942483L (no) 1995-01-02
IL110161A0 (en) 1994-10-07
NO991019L (no) 1995-01-02
AU6598794A (en) 1995-01-12
EP0924210B1 (de) 2004-08-18
NO307379B1 (no) 2000-03-27
JPH0853453A (ja) 1996-02-27
HU220609B1 (hu) 2002-03-28
EP0924210A1 (de) 1999-06-23
ES2170080T3 (es) 2002-08-01
FI943164A0 (fi) 1994-07-01
CA2127193C (en) 2005-04-12
DE69433955D1 (de) 2004-09-23
FI106962B (fi) 2001-05-15
DK0632039T3 (da) 2002-05-13
ES2222630T3 (es) 2005-02-01
JP2666118B2 (ja) 1997-10-22
NO306780B1 (no) 1999-12-20
CA2127193A1 (en) 1995-01-02
DE69433955T2 (de) 2005-09-08
AU682510B2 (en) 1997-10-09
TW254943B (de) 1995-08-21

Similar Documents

Publication Publication Date Title
DE69429742D1 (de) 2-[1-(1,3-Thiazolin-2-yl)azetidin-3-yl]thio-carbapenem-Derivate
DK0807630T3 (da) Heterocykliske forbindelser
ES2195510T3 (es) Derivados de imidazopiridina y procedimiento para prepararlos.
ATE271045T1 (de) Sauerstoffhaltige heterocyclische verbindungen
UY24010A1 (es) Nuevos pirrolocarbazoles
DK0717042T3 (da) Fremgangsmåde til fremstilling af 1-(4,5-dihydro-2-thiazolyl)-3-azetidin-thiol-derivater
EP0555479A4 (de)
NO931105D0 (no) Fremgangsmaate for fremtilling av 4-substituerte azetidinonderivater
DE69427100D1 (de) Herstellung von Beta-lactamverbindungen und Zwischenprodukte

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WYETH K.K., TOKIO/TOKYO, JP

8327 Change in the person/name/address of the patent owner

Owner name: PFIZER JAPAN INC., TOKIO/TOKYO, JP